Skip to main content

Table 1 The 21 best candidate genes that are MYCN-dependent and harbor recurrent, verified missense variants in HR-NB

From: Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma

Hugo Symbol

MYCN-associated expression

Case USI

Chromosome

Start_Position

Variant Classification

Mycn statues

Verification Method

AHCTF1

MA-hi

TARGET-30-PAPNEP

1

247,063,482

Missense

amp

 
 

TARGET-30-PASAZJ

1

247,014,426

Missense

non-amp

(2)

ALK

MA-hi

N130 T

2

29,286,167

Missense

amp

(1)

 

N160 T

2

29,286,167

Missense

gain

(1)

 

N744 T

2

29,286,167

Missense

non-amp

(1)

 

N198 T

2

29,297,200

Missense

non-amp

(1)

 

TARGET-30-PAKXDZ

2

29,445,213

Missense

amp

(3)

 

TARGET-30-PANRVJ

2

29,443,697

Missense

non-amp

(4)

 

TARGET-30-PARKNP

2

29,443,697

Missense

non-amp

(4)

 

TARGET-30-PARLTG

2

29,443,696

Missense

non-amp

(4)

 

TARGET-30-PARZIP

2

29,443,696

Missense

non-amp

(4)

 

TARGET-30-PAPRPR

2

29,443,695

Missense

amp

(4)

 

TARGET-30-PASVRU

2

29,443,695

Missense

amp

(4)

 

TARGET-30-PATFXV

2

29,443,695

Missense

amp

(4)

 

TARGET-30-PALAKE

2

29,443,695

Missense

amp

(3)

 

TARGET-30-PANZVU

2

29,443,695

Missense

non-amp

(3)

 

TARGET-30-PATFCY

2

29,436,875

Missense

non-amp

(4)

 

TARGET-30-PAINLN

2

29,436,860

Missense

non-amp

(3)

 

TARGET-30-PASKFV

2

29,432,664

Missense

amp

(4)

 

TARGET-30-PANWRR

2

29,432,664

Missense

non-amp

(4)

 

TARGET-30-PANXJL

2

29,432,664

Missense

non-amp

(4)

 

TARGET-30-PAPTFZ

2

29,432,664

Missense

amp

(4)

 

TARGET-30-PAPTLV

2

29,432,664

Missense

amp

(4)

 

TARGET-30-PARURB

2

29,432,664

Missense

non-amp

(4)

 

TARGET-30-PALNLU

2

29,432,664

Missense

non-amp

(3)

 

TARGET-30-PANBCI

2

29,432,664

Missense

amp

(3)

 

TARGET-30-PASAZJ

2

29,432,664

Missense

non-amp

(2) (4)

 

TARGET-30-PAREGK

2

29,443,695

Missense

non-amp

(2)(5)

ATM

MA-hi

TARGET-30-PANYGR

11

108,196,934

Silent

non-amp

 
 

TARGET-30-PANRHJ

11

108,200,975

Missense

non-amp

 
 

TARGET-30-PANRRW

11

108,196,798

Missense

non-amp

(2)

FANCM

MA-hi

TARGET-30-PASXRG

14

45,646,146

Missense

amp

(4)

 

TARGET-30-PARHUX

14

45,657,091

Splice_Site

amp

(4)

 

TARGET-30-PARETE

14

45,658,176

Nonsense

amp

(4)

 

N492 T

14

 

Mut. Splice Junction

non-amp

 

MRPS27

MA-hi

TARGET-30-PAPSKM

5

71,519,665

Missense

non-amp

(2)(5)

 

TARGET-30-PAPSKM

5

71,522,027

Splice_Site_GWAS SNP

non-amp

(2)(5)

MSH2

MA-hi

TARGET-30-PAITCI

2

47,641,416

Silent

non-amp

 
 

TARGET-30-PARKNP

2

47,693,815

Frame_Shift_Del

non-amp

(4)

 

N538 T

2

2,367,537

Protein Fusion

amp

 

MYCN

MA-hi

TARGET-30-PAPLSD

2

16,082,317

Missense

non-amp

(4)

 

TARGET-30-PARCRR

2

16,082,317

Missense

non-amp

(4)

 

TARGET-30-PARVNT

2

16,082,317

Missense

non-amp

(4)

 

TARGET-30-PASLGS

2

16,082,317

Missense

non-amp

(2)(3)(5)

 

NB-1744-Tumor

19

19,337,844

Missense

 

(4)

 

N619 T

2

16,003,271

Missense

amp

(1)

NCAN

MA-hi

TARGET-30-PANIPC

19

19,337,844

Missense

amp

(4)

 

TARGET-30-PAPKXS

19

19,338,389

Missense

non-amp

(4)

 

TARGET-30-PANLET

19

19,359,524

Missense

non-amp

(4)

STAG1

MA-hi

TARGET-30-PAIPGU

3

136,117,607

Missense

non-amp

 
 

TARGET-30-PARDCK

3

136,078,044

Missense

non-amp

 
 

TARGET-30-PAPZFW

3

136,057,265

Frame_Shift_Del

non-amp

(4)

BARD1

MA-hi

TARGET-30-PATGWT

2

215,595,215

Nonsense; 1p-;17q+

amp

(3)

 

TARGET-30-PAHYWC

2

215,657,051

Nonsense; 9p-; 10q-;17q+

amp

(3)

 

GWAS

2

215,672,546

GWAS SNP

 

(6)

 

GWAS

2

215,635,794

GWAS SNP

 

(6)

ARID1A

MN-hi

TARGET-30-PALNLU

1

27,099,000

Missense

non-amp

(3)

 

TARGET-30-PALXHW

1

27,106,214

Missense

non-amp

(3)

 

N554 T

1

26,970,220

DEL

amp

(1)

CACNB3

MN-hi

TARGET-30-PAMDAL

12

49,220,231

Missense

amp

(4)

 

N608 T

12

47,505,015

Missense

amp

(1)

IL16

MN-hi

TARGET-30-PAIMDT

15

81,561,966

Missense

non-amp

(3)

 

N170 T

15

79,385,873

Missense

non-amp

(1)

INPP5D

MN-hi

TARGET-30-PANUIF

2

234,070,424

Missense

non-amp

(4)

 

TARGET-30-PANRVJ

2

234,098,527

Missense

non-amp

(4)

LRRTM4

MN-hi

TARGET-30-PATEPF

2

77,746,658

Frame_Shift_Ins

non-amp

(4)

 

N717 T

2

77,600,317

GWAS SNP

amp

(1)

MLL5

MN-hi

TARGET-30-PARBLH

7

104,748,301

Missense

non-amp

 
 

TARGET-30-PANYGR

7

104,753,479

Missense

non-amp

(2)

 

N198 T

7

104,437,581–104,447,802

Deletion

non-amp

 

NCAM1

MN-hi

TARGET-30-PAPZFW

11

113,130,966

Silent

non-amp

(4)

 

TARGET-30-PASGUT

11

113,077,981

Splice_Site

non-amp

(4)

NRAS

MN-hi

TARGET-30-PANBSP

1

115,258,745

Missense

non-amp

(4)

 

TARGET-30-PAPTMM

1

115,256,530

Missense

amp

(2)(5)

SYNRG

MN-hi

TARGET-30-PARDIW

17

35,930,941

Missense

non-amp

 
 

TARGET-30-PASAZJ

17

35,956,340

Missense

non-amp

(2)(5)

TLN2

MN-hi

TARGET-30-PASRFS

15

63,029,117

Silent

non-amp

 
 

TARGET-30-PARNNG

15

63,030,490

Missense

non-amp

 
 

TARGET-30-PARIRD

15

62,942,372

Missense

amp

(2)(5)

LMO1

MN-hi

GWAS

10

8,252,853

GWAS SNP

 

(6)

 

GWAS

10

8,238,639

GWAS SNP

 

(6)

  1. The information was collected from the Table S3 of Pugh 2013 Nature paper and the Tables S1, S3, S6 of Molenaar 2012 Nature paper. All patients are with high-risk neuroblastoma (TARGET_NBL_clinicalCovariates20120702.txt)
  2. Validation Method: (1) linkage disequilibrium analysis; (2) PCR/HiSeq; (3) Sequenom; (4) PCR/MiSeq; (5) PCR/Sanger; (6) GWAS